Literature DB >> 2038175

Immunogenetic markers in patients with Graves' disease.

E Schifferdecker1, P Kühnl, K Schöffling, B Manfras, G Holzberger, W Spielmann, B O Böhm.   

Abstract

110 carefully characterized Caucasoid patients with Graves' disease were tested for HLA class I and class II antigens. Compared with Caucasian controls (n = 193), the frequencies of HLA B8, Cw7 and DR3 were significantly increased (pc less than 0.05). In the subgroups with and without exophthalmos, HLA A3 exhibited a negative but insignificant association with the eye involvement, while A19 and Cw2 showed positive, however even weaker correlations with eye disease. HLA DR5 was associated with relapsing thyrotoxicosis, whereas HLA DR7 and B12 were negatively correlated with relapse. These results confirm the positive correlation of HLA B8 and DR3 with Graves' disease and reveal a not yet observed association with Cw7. Reported correlations of antigen frequencies with eye disease and relapsing thyrotoxicosis could not be confirmed. Other previously unknown, however subtle differences in disease subgroups were observed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2038175     DOI: 10.1007/bf01666851

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  25 in total

1.  HL-A8: a genetic link with thyrotoxicosis.

Authors:  S Whittingham; P J Morris; F I Martin
Journal:  Tissue Antigens       Date:  1975-07

2.  Prediction of relapse in hyperthyroid Graves' disease.

Authors:  A M McGregor; B R Smith; R Hall; M M Petersen; M Miller; P J Dewar
Journal:  Lancet       Date:  1980-05-24       Impact factor: 79.321

3.  [Study of the HL-A system in Basedow's disease (author's transl)].

Authors:  C Jaffiol; J Seignalet; L Baldet; M Robin; H Lapinski; J Mirouze
Journal:  Ann Endocrinol (Paris)       Date:  1976 Mar-Apr       Impact factor: 2.478

Review 4.  HLA and disease 1982--a survey.

Authors:  A Svejgaard; P Platz; L P Ryder
Journal:  Immunol Rev       Date:  1983       Impact factor: 12.988

5.  Graves' disease and HLA: clinical and epidemiologic associations.

Authors:  N R Farid; E Stone; G Johnson
Journal:  Clin Endocrinol (Oxf)       Date:  1980-12       Impact factor: 3.478

6.  A prospective study of the relationship between relapse of hyperthyroid Graves' disease after antithyroid drugs and HLA haplotype.

Authors:  H Allannic; R Fauchet; Y Lorcy; M Gueguen; A M Le Guerrier; B Genetet
Journal:  J Clin Endocrinol Metab       Date:  1983-10       Impact factor: 5.958

7.  HLA and hyperthyroidism in Ireland.

Authors:  R McKenna; M Kearns; D Sugrue; M I Drury; C F McCarthy
Journal:  Tissue Antigens       Date:  1982-02

8.  HLA antigens in Graves' disease.

Authors:  K Bech; B Lumholtz; J Nerup; M Thomsen; P Platz; L P Ryder; A Svejgaard; K Siersbaek-Nielsen; J M Hansen; J H Larsen
Journal:  Acta Endocrinol (Copenh)       Date:  1977-11

9.  The genetics of Graves' disease: HLA and disease susceptibility.

Authors:  V Stenszky; L Kozma; C Balázs; S Rochlitz; J C Bear; N R Farid
Journal:  J Clin Endocrinol Metab       Date:  1985-10       Impact factor: 5.958

10.  HLA-DR3 and HLA-DR5 associated thyrotoxicosis--two different types of toxic diffuse goiter.

Authors:  H Schleusener; G Schernthaner; W R Mayr; P Kotulla; U Bogner; R Finke; H Meinhold; K Koppenhagen; K W Wenzel
Journal:  J Clin Endocrinol Metab       Date:  1983-04       Impact factor: 5.958

View more
  4 in total

1.  Trends in diagnostic and therapeutic criteria in Graves' disease in the last 10 years.

Authors:  F Escobar-Jiménez; M L Férnandez-Soto; V Luna-López; M Quesada-Charneco; D Glinoer
Journal:  Postgrad Med J       Date:  2000-06       Impact factor: 2.401

2.  HLA-DRB3 gene alleles in Caucasian patients with Graves' disease.

Authors:  B O Boehm; P Kühnl; B J Manfras; M Chen; J C Lee; G Holzberger; S Seidl; E Schifferdecker; P M Schumm-Draeger; K H Usadel
Journal:  Clin Investig       Date:  1992-10

3.  Antibodies to Ro/La, Cenp-B, and snRNPs antigens in autoimmune hepatitis of North America versus Asia: patterns of immunofluorescence, ELISA reactivities, and HLA association.

Authors:  S Parveen; S A Morshed; K Arima; M Nishioka; A J Czaja; W C Chow; H S Ng
Journal:  Dig Dis Sci       Date:  1998-06       Impact factor: 3.199

4.  HLA-DR3 and HLA-DR5 confer risk for autoantibody positivity against the thyroperoxidase (mic-TPO) antigen in healthy blood donors.

Authors:  B O Boehm; P Kühnl; C Löliger; U Ketzler-Sasse; G Holzberger; S Seidl; R Bäuerle; E Schifferdecker; K H Usadel
Journal:  Clin Investig       Date:  1993-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.